GoodRx price target lowered to $7 from $8 at Wells Fargo

Wells Fargo lowered the firm’s price target on GoodRx (GDRX) to $7 from $8 and keeps an Overweight rating on the shares. The firm’s discount Rx benchmark crowns GoodRx as the best discount platform, across both depth and breadth of generic Rx discounts, but competitive gap appears to be narrowing, likely limiting upside to the core business.